Sector News

Will Mylan boost its Perrigo bid? New securities filing suggests it won’t

June 29, 2015
Life sciences
Perrigo was none too fond of Mylan’s most recent offer when it made it back in April. Yet it looks like that’s the one Mylan’s sticking with–at least for now.
 
In a proxy filing from the generics giant, Mylan laid out the terms of its offer–$75 per share in cash and 2.3 Mylan shares for each Perrigo share. And that makes it seem “less likely Mylan will change” its proposal, Bernstein analyst Ronny Gal wrote in a note to investors on Monday.
 
Of course, those are the same terms Mylan laid out two months ago–terms that Perrigo said “significantly undervalued” its business. And since then, the Irish drugmaker’s CEO, Joseph Papa, has said he’s not opposed to a Mylan buyout at the right price–but that when it comes to finding one, the two companies are still “far apart.”
 
Mylan, for its part, blames that on Perrigo. “In recent weeks, Mylan has repeatedly offered to have constructive discussions with Perrigo regarding its current offer for Perrigo, but Perrigo has refused to engage in discussions,” it wrote in the new filing. And while Mylan says it still thinks it’s possible to work something out directly with Perrigo, it plans to push forward with the transaction regardless.
 
One reason: Sealing a Perrigo deal will thwart Mylan’s own unwanted suitor, Teva. The Israeli drugmaker has said its $40-billion-plus offer–one Mylan wants nothing to do with–is contingent on its target not buying Perrigo–or anyone else, for that matter.
 
So Mylan is working to do exactly that, a pursuit that’s included an investor roadshow that most recently stopped on its predator’s home turf. Last week, CFO John Sheehan met with Perrigo shareholders in Israel to tout the benefits of a tie-up; he also promised to list Mylan on the Tel Aviv stock exchange and keep open at least one Israeli manufacturing facility, Gal noted.
 
By Carly Helfand
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach